Clinical Trials Directory

Trials / Completed

CompletedNCT04662242

The Prognostic Impact of Selenium On Critical Surgical Patients

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
36 (actual)
Sponsor
Chang Gung Memorial Hospital · Academic / Other
Sex
All
Age
20 Years
Healthy volunteers
Not accepted

Summary

Selenium is an important trace element for human for its multiple roles such as the antioxidant activity. Previous evidences showed that critically ill patients may benefit from selenium supplement but the dose and results are controversial. Patients after operations for acute abdomen usually suffer from sepsis and stress. The aim of this study is to investigate the efficacy of selenium replacement in critical patients of acute abdomen, to see the impact on prognosis.

Detailed description

Acute abdomen is a common surgical emergency and is often the result of peritonitis due to an acute inflammatory process within abdominal cavity. Many of the patients with acute abdomen have severe sepsis and are critically ill that require an emergency surgery. The mortality rate of such patients are high because these patients usually have a profound pathophysiological dysregulation and multiple organ dysfunction. One of the mechanism of is the loss of anti-oxidative capacity of cells that fail to recover from ischemic-reperfusion injury. Selenium is an important cofactor that participate in the antioxidant activity of glutathione peroxidase reaction. There are evidences that critically ill patients may benefit from selenium supplement by better outcome and less mortality but the dose and results are still heterogenous and inconclusive. The aim of this study is to investigate the efficacy of selenium replacement in critical patients of acute abdomen, to see if there is a significant impact on prognosis, and to establish a clinical guide in the future.

Conditions

Interventions

TypeNameDescription
DRUGSelenium SupplementZelnite 400mcg/day in normal saline 100ml iv infusion for 7 days
DRUGnormal salinenormal saline 100ml iv infusion for 7 days

Timeline

Start date
2020-12-01
Primary completion
2022-10-31
Completion
2022-11-16
First posted
2020-12-10
Last updated
2023-02-10

Locations

1 site across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT04662242. Inclusion in this directory is not an endorsement.